These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29452300)

  • 41. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
    Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
    Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Treatment reduction in well-controlled rheumatoid arthritis. State of knowledge].
    Krüger K; Edelmann E
    Z Rheumatol; 2015 Jun; 74(5):414-20. PubMed ID: 26085073
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study.
    Yoshida K; Radner H; Mjaavatten MD; Greenberg JD; Kavanaugh A; Kishimoto M; Matsui K; Okada M; Reed G; Saeki Y; Tohma S; Kremer J; Solomon DH
    J Rheumatol; 2015 Dec; 42(12):2238-46. PubMed ID: 26523025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
    Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
    Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.
    van Herwaarden N; van der Maas A; Minten MJ; van den Hoogen FH; Kievit W; van Vollenhoven RF; Bijlsma JW; van den Bemt BJ; den Broeder AA
    BMJ; 2015 Apr; 350():h1389. PubMed ID: 25858265
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictors of flare in rheumatoid arthritis patients with persistent clinical remission/low disease activity: Data from the TARAC cohort.
    Chaiamnuay S; Jiemjit S; Songdechaphipat W; Narongroeknawin P; Pakchotanon R; Asavatanabodee P
    Medicine (Baltimore); 2022 Aug; 101(32):e29974. PubMed ID: 35960097
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice.
    Lenert A; Lenert P
    Clin Rheumatol; 2017 Jan; 36(1):1-8. PubMed ID: 27896522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.
    Kobelt G
    Value Health; 2014 Jul; 17(5):537-44. PubMed ID: 25128046
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.
    Navarro-Millán I; Sattui SE; Curtis JR
    Clin Ther; 2013 Nov; 35(11):1850-61.e1. PubMed ID: 24156821
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial.
    Uhrenholt L; Christensen R; Dreyer L; Hauge EM; Schlemmer A; Loft AG; Rasch M; Horn HC; Gade KH; Østgård RD; Taylor PC; Duch K; Kristensen S
    Scand J Rheumatol; 2023 Sep; 52(5):481-492. PubMed ID: 36745114
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tapering of Etanercept is feasible in patients with Rheumatoid Arthritis in sustained remission: a pragmatic randomized controlled trial.
    Bertrand D; Stouten V; De Cock D; Pazmino S; Doumen M; de Wergifosse I; Joly J; Badot V; Corluy L; Hoffman I; Taelman V; De Knop K; Geens E; Langenaken C; Lenaerts JL; Lenaerts J; Walschot M; Mannaerts J; Westhovens R; Verschueren P
    Scand J Rheumatol; 2022 Nov; 51(6):470-480. PubMed ID: 34514929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up.
    Cárdenas MJ; de la Fuente S; Castro-Villegas MC; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérrez J; Escudero-Contreras A; Del Prado JR; Collantes-Estévez E; Font P
    Rheumatol Int; 2017 Oct; 37(10):1701-1708. PubMed ID: 28597307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
    Lubrano E; De Socio A; Perrotta FM
    J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
    l'Ami MJ; Kneepkens EL; Nurmohamed MT; Krieckaert CLM; Visman IM; Wolbink GJ
    Clin Exp Rheumatol; 2017; 35(3):431-437. PubMed ID: 28079512
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations.
    Bastida C; Huitema ADR; l'Ami MJ; Ruiz-Esquide V; Wolbink GJ; Sanmartí R; Soy D
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1417-1425. PubMed ID: 32514745
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of progressively reducing biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in persistent remission: a study protocol for a non-inferiority randomized, controlled, single-blind trial.
    Lei S; Li Z; Zhang X; Zhou S
    Trials; 2022 Jul; 23(1):600. PubMed ID: 35897052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature.
    Chen DY; Lau CS; Elzorkany B; Hsu PN; Praprotnik S; Vasilescu R; Marshall L; Llamado L
    Int J Rheum Dis; 2018 Feb; 21(2):362-372. PubMed ID: 29205904
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
    Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
    Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
    Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.